Vintriptol, a tryptophan ester of vinblastine, was developed as an antitumor drug. Vintriptol participated in a phase I clinical trial for the treatment of non-small cell lung cancer. As a result, was found a recommended dose for stage II. However, the further development of vintriptol was discontinued.

Nibroxane, 5-bromo-2-methyl-5-nitro-m-dioxane, is a topically effective antimicrobial agent with a broad spectrum of activity. Nibroxane is unusual in that it not only possesses high microbiocidal activity against Gram positive (Staphylococcus uureus) and Gram negative (Pseudomonas aeruginosa) bacteria but also against yeasts (Candida albicans) and moulds (Aspergillus niger). In addition, the 5-bromo-5-nitro-m-dioxanes have, as a class of compounds, the distinct advantage of being chemically stable over a wide pH range. This inherent stability, coupled with its broad spectrum of microbiocidal activity, makes nibroxane an excellent candidate as a preservative for cosmetic and pharmaceutical formulations.

Dieldrin is an organochlorine pesticide belonging to the class of substances which are known to have a toxic effect on various physiological systems of the human body. Despite an imposed ban on their manufacture and commercial use, these pesticides can still be detected in high probability areas of consumption such as agriculture land. Dieldrin has been epidemiologically associated with an increased risk for Parkinson's disease (PD). Early studies identifying dieldrin as an antiandrogen estrogen mimetic have been contradicted by more recent studies which do not show any estrogenic activity.

Solabegron (GW427353), a beta-3 adrenoceptor agonist, is in development with AltheRx (now Velicept Therapeutics) for the treatment of irritable bowel syndrome (IBS) and overactive bladder (OAB). Solabegron was discovered and first developed by GlaxoSmithKline. It was acquired by AltheRx, which merged with Velicept in 2015 to continue development of the program. Solabegron has been tested in over 800 study subjects in a twice-a-day formulation and demonstrated efficacy in the treatment of OAB as well as IBS. A once daily formulation designed to optimize patient convenience as well as efficacy has been developed and is currently being evaluated in a phase 2b dose ranging clinical trial. A Phase 2b dose ranging study with the twice daily formulation also began enrollment in Q1 2018.

LEDOXANTRONE, a benzothiopyranoindazole, is an intercalating agent. Its mechanism of action is probably due to DNA helicase blockade. It was under development for the treatment of prostate and ovarian cancers.

Tiprinast (MJ 12175) is one of a series of thienopyrimidine-carboxylic acids synthesized as possible antiallergy compounds. In clinical studies it has been shown to be efficacious in preventing the symptoms of ragweed hay fever when used as a nasal spray. Tiprinast has been shown to resemble disodium cromoglycate (cromolyn) in biologic activity in a variety of antigen-induced allergic test systems. Both compounds inhibit passive cutaneous anaphylaxis in the rat, histamine release from rat peritoneal mast cells and nasal constriction due to antigen in the rat. In all cases tiprinast is more potent than cromolyn and also longer acting. Tiprinast, like cromolyn, appears to elicit a cardiac reflex (Bezold-Jarisch) in the anesthetized dog.

Trepipam is a benzazepine derivative. It is a D1-dopamine antagonist. Trepipam significantly reduced aggression in behaviorally disturbed adolescents and in acute schizophrenics without producing concomitant sedation. Trepipam specifically reduces aggressive and hyperactive behaviors in a wide range of laboratory tests in various species, without producing signs of overt CNS depression or neurological impairment. The drug is effective in reducing many forms of aggression including brain stimulated emotional behavior. Trepipam actually had little effect on gross behavior in mice or rats and only produced ataxia at lethal doses.

Solypertine (WIN-18413-2) is an antiadrenergic drug. Solypertine selectively blocked the conditioned avoidance response in rats. Solypertine potentiated hexobarbitone sleeping time, caused hypothermia and afforded protection from amphetamine toxicity inaggregated mice.